A Novel And Unique Protein I-body For The Treatment Of Chronic Kidney Disease Through Targeting CXCR4
Funder
National Health and Medical Research Council
Funding Amount
$768,340.00
Summary
Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease, and premature death. Kidney transplantation and dialysis are the only options for the management of CKD, which results in a significant burden on the health system. The central aim of this project is to develop a novel therapeutic strategy to limit/reverse CKD, which will lead to a researcher-industry partnership in discovery of novel therapeutic agent.
Treatment Of Diverse Renal Diseases With Regulatory Cells
Funder
National Health and Medical Research Council
Funding Amount
$566,946.00
Summary
Chronic kidney disease (CKD) is a major cause of death and disability in the Australian population. Current treatments for CKD are non-specific and frequently ineffective. As a consequence, kidney failure progresses to the stage where patients require dialysis or tranplantation to remain alive. Every year more than 1700 Australians require kidney replacement therapy for this reason and many more die of kidney failure or its complications. Some forms of kidney disease are self-limited whereas oth ....Chronic kidney disease (CKD) is a major cause of death and disability in the Australian population. Current treatments for CKD are non-specific and frequently ineffective. As a consequence, kidney failure progresses to the stage where patients require dialysis or tranplantation to remain alive. Every year more than 1700 Australians require kidney replacement therapy for this reason and many more die of kidney failure or its complications. Some forms of kidney disease are self-limited whereas others are characterised by chronic kidney scarring and the eventual development of endstage disease. This project will explore whether natural protective cells (regulatory T cells) can be used to treat differing types of CKD, including those characterised predominantly by inflammation or by fibrosis. In addition, the protective mechanisms of regulatory T cells (including their interaction with resident kidney cells) will be explored, as will ways of increasing the efficacy of regulatory T cell therapy.Read moreRead less
Gamma-Delta Tregs, CD8 Tregs And Selected Natural Tregs To Treat Renal Injury
Funder
National Health and Medical Research Council
Funding Amount
$605,096.00
Summary
Chronic kidney disease (CKD) progresses due to ongoing damage to the kidney. We have identified three types of white cells that can reduce kidney damage in CKD. The first is a unique set of gamma-delta T cells that expand in the kidney and protect against injury. The second is a restricted set of CD8 T cell that can protect against kidney injury. The third are targeted natural regulatory T cells. These studies develop each of these three subsets as potential cellular therapies in CKD.
DNA Vaccination Using Chemokine And Costimulatory Pathways As A Treatment For Chronic Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$450,390.00
Summary
Chronic kidney disease (CKD) is a great burden on Australia. Treatments are mostly ineffective. Our DNA vaccination against mediators of inflammation can protect against CKD. On the basis of ongoing studies we have identified 5 candidate molecules involved in recruitment and activation of inflammatory cells. We outline studies to generate DNA vaccines to these molecules, enhance their efficacy, and test them in models that represent the 3 most important causes of human CKD.
Tubulointerstitial Epigenetics- The Underlying Basis Of Progressive Fibrosis In Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$378,940.00
Summary
Although the kidney has capacity to repair after mild injuries, ongoing or severe injury results in scarring (so-called fibrosis) and a progressive loss of kidney function. Understanding the mechanisms that regulate the transition from repair to fibrosis is important, because once fibrosis is initiated it can be extremely difficult to switch off or reverse.
Progression Of Kidney Damage In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$782,249.00
Summary
There is an overwhelming burden of chronic disease in Indigenous Australians. In order to attempt to improve kidney disease in this high-risk population, it is vital that we understand what factors contribute to rapid progression of kidney damage. This study will provide the evidence to design an intervention to slow progression of kidney disease in Indigenous Australians. It will also enable development of appropriate clinical guidelines for improved management of kidney disease.
The Effect Of Renal Transplantation And Extended Hours Haemodialysis On Cardiac MRI And Biomarkers.
Funder
National Health and Medical Research Council
Funding Amount
$107,750.00
Summary
Patients with chronic kidney disease (CKD) are at increased risk for cardiovascular disease (CVD). Asymptomatic patients demonstrate changes in cardiac imaging and elevation of cardiac biomarkers which predict outcome. This study will investigate serial cardiac imaging and cardiac biomarkers in patients undergoing live donor renal transplantation and extended hours haemodialysis. Results will enhance our understanding of cardiovascular disease in CKD leading to improved patient outcomes.
Targeting MicroRNA-200b In Diabetic Nephropathy Using Two Novel Delivery Systems
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Better treatments to prevent diabetic kidney disease are prioritized by government, commercial and philanthropic sectors. MicroRNA-based strategies limit kidney fibrosis in animal models of non-diabetic kidney disease. However, current delivery systems require optimization prior to human use. We have shown that microRNA-200b suppresses kidney fibrosis. We will study two delivery systems to deliver microRNA-200b to the kidney and to study its potential to prevent or limit diabetic kidney disease.